2. Anti-infection
  3. Dengue Virus

Dengue Virus

Dengue virus (DENV) belongs to the Flaviviridae family and is a small enveloped virus with a single-stranded positive-sense RNA of about 11kb in length and a granular spherical shape. DENV contains 4 serotypes: DENV serotype 1, DENV-2, DENV-3 and DENV-4. Envelope Protein E, NS3, NS5, etc. are effective targets for DENV inhibitors, which work by blocking viral entry, inhibiting protein processing and replication, and interfering with RNA capping. NS4B inhibitors can also disrupt related effects and inhibit the formation of viral replication complexes.

Dengue Virus Related Products (99):

Cat. No. Product Name Effect Purity
  • HY-B0421
    Mycophenolic acid Inhibitor 99.94%
    Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].
  • HY-15310
    Ivermectin Inhibitor
    Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import[1][2][3][4]. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[5].
  • HY-107433
    U18666A Inhibitor
    U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus[1].
  • HY-N0100
    Naringenin Inhibitor 99.27%
    Naringenin is the predominant flavanone in Citrus reticulata Blanco; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-dengue virus (DENV) activity.
  • HY-108462
    ML-SA1 Inhibitor 99.44%
    ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral[1].
  • HY-169847
    ZK-806450
    ZK-806450 is a compound with antiviral activity. ZK-806450 has a high binding potential to the allosteric binding site of the SARS-CoV-2 3CL protease. ZK-806450 can also specifically and stably bind to the GAG site of the dengue virus envelope protein[1][2].
  • HY-17043S3
    Loratadine-13C6 Inhibitor
    Loratadine-13C6 (SCH 29851-13C6) is 13C labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-dengue-virus (DENV) activity. Loratadine can inhibit immunologic release of inflammatory mediators.
  • HY-173018
    ML283 Inhibitor
    ML283 is a HCV NS3 helicase inhibitor (IC50: 2.6 μM). ML283 also inhibits DenV ATPase (IC50: 4.0 μM)[1].
  • HY-121663
    ST-148 Inhibitor
    ST-148 is a novel small molecule compound that has potent inhibitory effects against all four dengue virus serotypes. In the nonlethal AG129 mouse dengue virus infection model, ST-148 significantly reduced viremia and viral load in vital organs and tended to reduce plasma cytokine levels. Compound resistance was associated with the dengue virus capsid (C) gene, and the direct interaction of ST-148 with the C protein was presumed to be achieved through the protein's built-in fluorescence change in the presence of the compound. Therefore, ST-148 appears to interact with the dengue virus C protein and inhibit one or more unique steps of the viral replication cycle.
  • HY-N3942
    Glabranine Inhibitor
    Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus[1]. Glabranine forms interaction with the soluble ectodomain of DENV type 2 (DENV2) E protein[2].
  • HY-134665
    NITD-2 Inhibitor 99.36%
    NITD-2, a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly[1].
  • HY-100540B
    Golgicide A-2 Inhibitor 99.53%
    Golgicide A-2 (GCA-2), a Golgicide A (GCA) derivative, is the most active enantiomer of GCA. Golgicide A-2 displays high selectivity and efficiency in killing An. stephensi larvae and can be used for the research of dengue virus related diseases[1].
  • HY-19961
    KIN1408 Inhibitor 99.55%
    KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses[1][2].
  • HY-157550
    DENV-IN-12 Inhibitor
    DENV-IN-12 (Compound 6) is a derivative of N-methylcytisine thio, which inhibits DENV-1 and DENV-2. DENV-IN-12 displays robust antiviral activity against DENV-2, with EC50 values ranging from 0.002 to 0.005 μM in different cell lines[1].
  • HY-13986
    Merimepodib Inhibitor 99.27%
    Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
  • HY-16468
    Squalamine Inhibitor
    Squalamine (MSI-1256) is an aminosterol compound with broad-spectrum antiviral activity. Squalamine makes cells less conducive to certain viral replication by altering the electrostatic interactions in the inner membrane of host cells. Squalamine also has antibacterial and antitumor activities. Squalamine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria, fungi and protozoa. Squalamine inhibits tumor-related angiogenesis and the growth of human breast cancer cells. Squalamine restores the function of enteric nervous system in Parkinson,s disease mouse models[1][2][3][4][5].
  • HY-139602
    (+)-JNJ-A07 Inhibitor
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1].
  • HY-124662
    IHVR-19029 Inhibitor
    IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy[1][2][3][4].
  • HY-B0421A
    Mycophenolic acid sodium Inhibitor 99.98%
    Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].
  • HY-17043
    Loratadine Inhibitor 99.98%
    Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-dengue-virus (DENV) activity. Loratadine can inhibit immunologic release of inflammatory mediators.